<p>C2N Diagnostics and LSI Medience will pursue approval of PrecivityAD2, which reads two blood markers, in Japan. Picture 100 people whose PrecivityAD2 result comes back Positive. In the study behind the test’s US Food and Drug Administration (FDA) clearance, about 98 of them had amyloid in the brain.</p>